CP-870,893

DRUG3 trials

Sponsors

Abramson Cancer Center at Penn Medicine

Conditions

Adenocarcinoma PancreasAdvanced Solid TumorsSolid Tumors

Early Phase 1

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

CompletedNCT02157831

Abramson Cancer Center at Penn MedicineSolid Tumors

Start: 2005-07-31End: 2008-02-29Updated: 2018-08-17

Phase 1

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

CompletedNCT01456585

Abramson Cancer Center at Penn MedicineAdenocarcinoma Pancreas

Start: 2012-04-30End: 2013-04-30Target: 10Updated: 2018-08-27

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

CompletedNCT02225002

Abramson Cancer Center at Penn MedicineAdvanced Solid Tumors

Start: 2004-01-31End: 2006-02-28Updated: 2018-08-28